Tysabri and Embolic stroke - a phase IV clinical study of FDA data

Summary:

Embolic stroke is reported as a side effect among people who take Tysabri (natalizumab), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Nexium, and have Diabetes.

The phase IV clinical study analyzes which people have Embolic stroke when taking Tysabri. It is created by eHealthMe based on reports of 220,870 people who have side effects when taking Tysabri from the FDA, and is updated regularly.

What is Tysabri?

Tysabri has active ingredients of natalizumab. It is often used in multiple sclerosis. eHealthMe is studying from 221,369 Tysabri users. Check the latest studies of Tysabri.

What is Embolic stroke?

Embolic stroke (stroke due to obstruction due to an embolus) is found to be associated with 365 drugs and 542 conditions by eHealthMe. Check the latest studies of Embolic stroke.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 29, 2026

220,870 people reported to have side effects when taking Tysabri.
Among them, 17 people (0.01%) have Embolic stroke.

Among these 17 people:

How long have people been on Tysabri when they have Embolic stroke? *

What is the gender of people who have Embolic stroke when taking Tysabri? *

female: 76.47 %
male: 23.53 %

What is the age of people who have Embolic stroke when taking Tysabri? *

What are other drugs people take besides Tysabri? *

What are other side effects people have besides Embolic stroke? *

Speech Disorder: 4 people, 23.53%
Confusional State: 3 people, 17.65%
Depressed Mood: 3 people, 17.65%
Headache (pain in head): 3 people, 17.65%
Cerebral Haemorrhage (bleeding within the brain): 3 people, 17.65%
Memory Loss: 2 people, 11.76%
Poor Venous Access: 2 people, 11.76%
Ischaemic Stroke (stroke; caused by an interruption in the flow of blood to the brain): 2 people, 11.76%
Irritability: 2 people, 11.76%
Cognitive Disorder (mental health disorders affects learning, memory, perception, and problem solving): 2 people, 11.76%

What are the existing conditions these people have? *

Diabetes: 2 people, 11.76%
Weight Decreased: 1 person, 5.88%
Urinary Tract Infection: 1 person, 5.88%
Sleep Disorder: 1 person, 5.88%
Sedation: 1 person, 5.88%
Pain: 1 person, 5.88%
Inflammation: 1 person, 5.88%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 1 person, 5.88%
Diarrhea: 1 person, 5.88%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Tysabri and have Embolic stroke?

- Check whether Embolic stroke is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tysabri:

Tysabri (221,369 reports)

Embolic stroke treatments and more:

Embolic stroke (4,762 reports)

Browse all side effects of Tysabri:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Embolic stroke:

Embolic stroke (365 drugs)

Browse all the conditions that are associated with Embolic stroke:

Embolic stroke (542 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on natalizumab (the active ingredients of Tysabri) and Tysabri (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.